Literature DB >> 24668726

Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection.

Antonio Riva1, Melissa Laird, Armanda Casrouge, Arvydas Ambrozaitis, Roger Williams, Nikolai V Naoumov, Matthew L Albert, Shilpa Chokshi.   

Abstract

UNLABELLED: The pathogenesis of hepatitis C virus (HCV) infection is strongly influenced by the nature of the host's antiviral immunity. Counterintuitively, elevated serum concentrations of C-X-C chemokine 10 (CXCL10), a potent chemoattractant for antiviral T-cells and NK-cells, are associated with poor treatment outcomes in patients with chronic HCV. It has been reported that an N-terminal truncated form of CXCL10, generated by the protease dipeptidylpeptidase 4 (DPP4), can act as chemokine antagonist. We sought to investigate CXCL10 antagonism in the clinical outcome and evolution of acute HCV infection. We collected serial blood samples from 16 patients, at the clinical onset of acute HCV infection and at 12 standardized follow-up timepoints over the first year. Intact and truncated CXCL10 and DPP4 activity were quantified in all longitudinal samples. In addition, NK-cell frequency/phenotype, and HCV-specific T-cell responses were assessed. Subjects developing chronicity (n = 11) had higher concentrations of CXCL10 (P < 0.001), which was predominantly in a truncated form (P = 0.036) compared to patients who spontaneously resolved infection (n = 5). Truncated CXCL10 correlated with HCV-RNA (r = 0.40, P < 0.001) and DPP4 activity (r = 0.53, P < 0.001). Subjects who resolved infection had a higher frequency of HCV-specific interferon-gamma (IFNγ)-producing T-cells (P = 0.017) and predominance of cytotoxic NK-cells (P = 0.005) compared to patients who became chronic. Patients who became persistently infected had higher proportions of cytokine-producing NK-cells, which were correlated with concentrations of truncated CXCL10 (r = 0.92, P < 0.001).
CONCLUSION: This study provides the first evidence of chemokine antagonism during acute HCV infection. We suggest that the DPP4-CXCL10 axis inhibits antiviral innate and adaptive host immunity and favors establishment of viral persistence.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24668726     DOI: 10.1002/hep.27139

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  22 in total

1.  Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.

Authors:  Wenxin Xu; Maneka Puligandla; Judith Manola; Andrea J Bullock; Daniel Tamasauskas; David F McDermott; Michael B Atkins; Naomi B Haas; Keith Flaherty; Robert G Uzzo; Janice P Dutcher; Robert S DiPaola; Rupal S Bhatt
Journal:  Clin Cancer Res       Date:  2019-08-30       Impact factor: 12.531

2.  Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy.

Authors:  Rosa Barreira da Silva; Melissa E Laird; Nader Yatim; Laurence Fiette; Molly A Ingersoll; Matthew L Albert
Journal:  Nat Immunol       Date:  2015-06-15       Impact factor: 25.606

Review 3.  Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C.

Authors:  Andrea Crosignani; Antonio Riva; Silvia Della Bella
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

4.  Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.

Authors:  Eric G Meissner; Jérémie Decalf; Armanda Casrouge; Henry Masur; Shyam Kottilil; Matthew L Albert; Darragh Duffy
Journal:  PLoS One       Date:  2015-07-16       Impact factor: 3.240

5.  Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection.

Authors:  Behzad Hajarizadeh; François Mj Lamoury; Jordan J Feld; Janaki Amin; Elizabeth Keoshkerian; Gail V Matthews; Margaret Hellard; Gregory J Dore; Andrew R Lloyd; Jason Grebely; Tanya L Applegate
Journal:  Virol J       Date:  2016-02-24       Impact factor: 4.099

Review 6.  Dysregulation of Chemokine/Chemokine Receptor Axes and NK Cell Tissue Localization during Diseases.

Authors:  Giovanni Bernardini; Fabrizio Antonangeli; Valentina Bonanni; Angela Santoni
Journal:  Front Immunol       Date:  2016-10-06       Impact factor: 7.561

7.  Identification of the transcripts associated with spontaneous HCV clearance in individuals co-infected with HIV and HCV.

Authors:  Yue Chen; Chengli Shen; Debjani Guha; Ming Ding; Scott Kulich; Aiymkul Ashimkhanova; Charles Rinaldo; Eric Seaberg; Joseph B Margolick; Valentina Stosor; Otoniel Martínez-Maza; Phalguni Gupta
Journal:  BMC Infect Dis       Date:  2016-11-22       Impact factor: 3.090

8.  Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post-translational modification: prospective placebo-controlled clinical studies.

Authors:  Jérémie Decalf; Kristin V Tarbell; Armanda Casrouge; Jeffrey D Price; Grace Linder; Estelle Mottez; Philippe Sultanik; Vincent Mallet; Stanislas Pol; Darragh Duffy; Matthew L Albert
Journal:  EMBO Mol Med       Date:  2016-06-01       Impact factor: 12.137

9.  The Foot-and-Mouth Disease Carrier State Divergence in Cattle.

Authors:  Carolina Stenfeldt; Michael Eschbaumer; Steven I Rekant; Juan M Pacheco; George R Smoliga; Ethan J Hartwig; Luis L Rodriguez; Jonathan Arzt
Journal:  J Virol       Date:  2016-06-24       Impact factor: 5.103

Review 10.  Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands.

Authors:  Mieke Metzemaekers; Vincent Vanheule; Rik Janssens; Sofie Struyf; Paul Proost
Journal:  Front Immunol       Date:  2018-01-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.